3 months ago
1
AstraZeneca Pharma India Ltd connected Tuesday (February 10, 2026) said it has received support from India's cause regulator to marketplace Durvalumab solution for infusion utilized successful crab attraction for an further indication.
The institution has received support from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, to import for merchantability and organisation of Durvalumab solution for infusion of strengths 120 mg/2.4 ml and 500 mg/10 ml (brand sanction Imfinzi) for an further indication, AstraZeneca Pharma said successful a regulatory filing.
Through this approval, Durvalumab successful operation with carboplatin and paclitaxel is indicated for the first-line attraction of adults with superior precocious oregon recurrent endometrial crab who are candidates for systemic therapy, followed by attraction attraction with Durvalumab arsenic monotherapy successful endometrial crab which is mismatch repair deficient (dMMR).
The receipt of this support paves mode for the selling of Durvalumab solution for infusion 120 mg/2.4 mL and 500 mg/10 mL (Imfinzi) successful India for the specified further indication, taxable to the receipt of related statutory approvals, it added.
